Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | EMBARK: final OS results of enzalutamide in hrBCR prostate cancer

Neal Shore • 19 Oct 2025
ESMO 2025
Genitourinary Cancer Prostate Cancer Enzalutamide Leuprolide
EMBARK

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses final overall survival results from the Phase III EMBARK trial (NCT02319837) of enzalutamide plus leuprolide or enzalutamide monotherapy versus leuprolide alone in patients with high-risk biochemically recurrent (hrBCR) prostate cancer. Combination therapy significantly reduced the risk of death compared with leuprolide alone and delayed disease progression and skeletal events. These findings confirm the long-term survival and clinical benefits of enzalutamide-based therapy as a standard of care in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Neal Shore

EMBARK: long-term remissions with hormonal therapy in prostate cancer
1:44
EMBARK: long-term remissions with hormonal therapy in prostate cancer
Neal Shore • 26 Feb 2026
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
1:54
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
Neal Shore • 26 Feb 2026
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
1:39
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
Neal Shore • 26 Feb 2026
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
1:36
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
Neal Shore • 26 Feb 2026

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals